Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival AdvantageSALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene ...
pharmaphorum8d
Denali's ALS programme suffers another setback
Nevertheless, the new disappointment with DNL343 is another major disappointment to ALS patients, who have limited drug ...
Clene Inc.: Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8 Treatment
Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment ...
Morningstar3d
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
78% of participants across both groups received standard ALS background therapy (riluzole, edaravone, or both) at baseline. These results are consistent with previous survival benefits observed in ...
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science ...
Medscape19d
ALS Trials Fail to Meet Key Endpoints…But It’s Still a Win and Here’s Why
Riluzole blocks glutamate to protect nerve cells, while edaravone slows damage from free radicals, but both offer limited benefits. In platform trials, pooling control group patients boosts ...
pharmaphorum1d
Amylyx ALS drug draws criticism over $158,000 price tag
The third ALS treatment to be given FDA approval, following Mitsubishi Tanabe’s Radicava ($170,000 per year) and generic drug riluzole – Relyvrio is priced at around $12,500 per 28-day ...
MedPage Today on MSN15d
Novel Agent Safe in ALS, Phase II Study Suggests
Tetramethylpyrazine nitrone was safe for people with amyotrophic lateral sclerosis (ALS), but neither a high nor low daily dose of the drug outperformed placebo for the primary outcome in a phase II ...
Hosted on MSN21d
New Zealand's Walk to Defeat Motor Neurone Disease takes its next step
Gauld highlighted the publicly funded MND drug Riluzole was currently only available in a tablet form. "If we could have a liquid Riluzole that would definitely reduce the burden, we need to be ...
National Institute for Health and Care Excellence26d
In development: Guidance, quality standards and advice
Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257] Technology appraisal guidance TBC Tislelizumab in combination for untreated advanced non-small-cell lung cancer ID6162 ...
National Institute for Health and Care Excellence19d
Awaiting development: Guidance and quality standards
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315] Technology appraisal guidance Marstacimab for treating ...